Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Collegium Pharmaceutical (COLL) over the last 10 years, with Q3 2025 value amounting to $78.2 million.

  • Collegium Pharmaceutical's Free Cash Flow rose 94658.66% to $78.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $289.3 million, marking a year-over-year increase of 5034.09%. This contributed to the annual value of $203.3 million for FY2024, which is 2587.06% down from last year.
  • Per Collegium Pharmaceutical's latest filing, its Free Cash Flow stood at $78.2 million for Q3 2025, which was up 94658.66% from $72.4 million recorded in Q2 2025.
  • Collegium Pharmaceutical's Free Cash Flow's 5-year high stood at $99.7 million during Q2 2023, with a 5-year trough of -$25.4 million in Q1 2022.
  • In the last 5 years, Collegium Pharmaceutical's Free Cash Flow had a median value of $54.6 million in 2025 and averaged $47.7 million.
  • As far as peak fluctuations go, Collegium Pharmaceutical's Free Cash Flow tumbled by 22621.88% in 2022, and later skyrocketed by 94658.66% in 2025.
  • Over the past 5 years, Collegium Pharmaceutical's Free Cash Flow (Quarter) stood at $35.7 million in 2021, then skyrocketed by 83.24% to $65.4 million in 2022, then grew by 11.91% to $73.2 million in 2023, then increased by 14.9% to $84.1 million in 2024, then dropped by 6.93% to $78.2 million in 2025.
  • Its Free Cash Flow was $78.2 million in Q3 2025, compared to $72.4 million in Q2 2025 and $54.6 million in Q1 2025.